BioXcel Therapeutics (BTAI) Competitors $0.34 +0.03 (+8.12%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BTAI vs. CNTB, SPRO, AADI, MURA, IVVD, KRON, IMMX, IMRX, ALTS, and STTKShould you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Connect Biopharma (CNTB), Spero Therapeutics (SPRO), Aadi Bioscience (AADI), Mural Oncology (MURA), Invivyd (IVVD), Kronos Bio (KRON), Immix Biopharma (IMMX), Immuneering (IMRX), Janone (ALTS), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry. BioXcel Therapeutics vs. Connect Biopharma Spero Therapeutics Aadi Bioscience Mural Oncology Invivyd Kronos Bio Immix Biopharma Immuneering Janone Shattuck Labs BioXcel Therapeutics (NASDAQ:BTAI) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, community ranking, analyst recommendations, earnings and media sentiment. Is BTAI or CNTB more profitable? Connect Biopharma has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -3,119.33%. Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics-3,119.33% N/A -105.04% Connect Biopharma N/A N/A N/A Does the media favor BTAI or CNTB? In the previous week, BioXcel Therapeutics had 2 more articles in the media than Connect Biopharma. MarketBeat recorded 3 mentions for BioXcel Therapeutics and 1 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.88 beat BioXcel Therapeutics' score of -1.00 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Overall Sentiment BioXcel Therapeutics Negative Connect Biopharma Very Positive Which has better earnings and valuation, BTAI or CNTB? Connect Biopharma has higher revenue and earnings than BioXcel Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioXcel Therapeutics$2.28M6.40-$179.05M-$2.16-0.16Connect Biopharma$24.12M2.18-$59.50MN/AN/A Do institutionals & insiders have more ownership in BTAI or CNTB? 30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 28.7% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts prefer BTAI or CNTB? BioXcel Therapeutics currently has a consensus target price of $5.00, indicating a potential upside of 1,366.28%. Connect Biopharma has a consensus target price of $8.00, indicating a potential upside of 741.31%. Given BioXcel Therapeutics' higher possible upside, research analysts plainly believe BioXcel Therapeutics is more favorable than Connect Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, BTAI or CNTB? BioXcel Therapeutics has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.34, meaning that its share price is 134% less volatile than the S&P 500. Does the MarketBeat Community favor BTAI or CNTB? BioXcel Therapeutics received 225 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 72.00% of users gave Connect Biopharma an outperform vote while only 67.50% of users gave BioXcel Therapeutics an outperform vote. CompanyUnderperformOutperformBioXcel TherapeuticsOutperform Votes24367.50% Underperform Votes11732.50% Connect BiopharmaOutperform Votes1872.00% Underperform Votes728.00% SummaryConnect Biopharma beats BioXcel Therapeutics on 8 of the 15 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition Export to ExcelMetricBioXcel TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.48M$6.57B$5.10B$9.08BDividend YieldN/A2.97%4.90%4.21%P/E Ratio-0.1610.5090.8717.14Price / Sales6.40195.381,112.67116.85Price / CashN/A57.1642.1437.88Price / Book-0.185.104.784.78Net Income-$179.05M$151.51M$119.77M$225.60M7 Day Performance-17.25%-2.12%-1.87%-1.23%1 Month Performance-40.24%-3.11%11.46%3.07%1 Year Performance-88.52%11.52%30.49%16.48% BioXcel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics3.9859 of 5 stars$0.34+8.1%$5.00+1,366.3%-88.5%$13.48M$2.28M-0.1690Negative NewsGap DownCNTBConnect Biopharma3.4695 of 5 stars$1.08-3.4%$8.00+640.7%+11.9%$59.68M$24.12M0.00110Positive NewsGap DownSPROSpero Therapeutics4.5434 of 5 stars$1.09+1.9%$5.00+358.7%-29.3%$59.43M$103.78M15.2946Analyst DowngradeNews CoveragePositive NewsGap UpAADIAadi Bioscience1.63 of 5 stars$2.37-1.7%$1.67-29.7%+64.6%$58.41M$25.07M-1.0640News CoverageGap UpMURAMural Oncology3.0891 of 5 stars$3.41-6.3%$16.00+369.2%-9.1%$58.04MN/A-0.40119IVVDInvivyd3.8001 of 5 stars$0.48-12.2%$7.89+1,542.5%-87.0%$57.44M$11.56M-0.28100News CoverageGap DownKRONKronos Bio3.353 of 5 stars$0.95-3.1%$1.63+71.2%-14.5%$57.29M$9.86M-0.69100IMMXImmix Biopharma2.8804 of 5 stars$2.06+1.0%$7.00+239.8%-67.7%$56.67MN/A-2.479News CoverageIMRXImmuneering3.4129 of 5 stars$1.76+7.6%$12.80+627.5%-70.1%$54.63M$320,000.00-0.8360News CoverageALTSJanoneN/A$3.83-2.3%N/AN/A$53.88M$7.11M0.00170Gap UpSTTKShattuck Labs2.6767 of 5 stars$1.11-3.1%$8.67+684.3%-82.2%$52.75M$1.66M-0.75100Positive News Related Companies and Tools Related Companies Connect Biopharma Alternatives Spero Therapeutics Alternatives Aadi Bioscience Alternatives Mural Oncology Alternatives Invivyd Alternatives Kronos Bio Alternatives Immix Biopharma Alternatives Immuneering Alternatives Janone Alternatives Shattuck Labs Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BTAI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BTAI Stock Alerts